Solaria Energia y Medio Stock (OTC: SEYMF)

Latest news for Solaria Energia y Medio (OTC:SEYMF) Stock

Solaria Energia y Medio Ambiente SA is a solar photovoltaic (PV) power generation company. It is also engaged in the solar power plant custom operation and maintenance services and development and management of PV projects. The company owns, manages and operates PV plants in Spain, Italy, Uruguay, Greece and Brazil.

SOLARIA ENERGIA Y MDO AMB by Solaria Energia Y Medio Ambienete SA

Solaria Energia y Medio Ambiente SA

Solaria Energia y Medio

&nbsp;

<h2>Upgrades</h2>

<ul>
	<li>BMO Capital upgraded the previous rating for BRP Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) from Market Perform to Outperform. For the second quarter, BRP had an EPS of $2.35, compared to year-ago quarter EPS of $0.83. At the moment, the stock has a 52-week-high of $101.08 and a 52-week-low of $46.90. BRP closed at $100.33 at the end of the last trading period.</li>
	<li>Guggenheim upgraded the previous rating for Southern Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) from Neutral to Buy. In the second quarter, Southern showed an EPS of $0.84, compared to $0.78 from the year-ago quarter. At the moment, the stock has a 52-week-high of $67.46 and a 52-week-low of $51.22. Southern closed at $66.27 at the end of the last trading period.</li>
	<li>For Methanex Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>), Barclays upgraded the previous rating of Equal-Weight to Overweight. Methanex earned $1.24 in the second quarter, compared to $0.84 in the year-ago quarter. The current stock performance of Methanex shows a 52-week-high of $49.27 and a 52-week-low of $21.67. Moreover, at the end of the last trading period, the closing price was at $37.91.</li>
	<li>According to Barclays, the prior rating for Cirrus Logic Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) was changed from Equal-Weight to Overweight. Cirrus Logic earned $0.54 in the first quarter, compared to $0.53 in the year-ago quarter. The current stock performance of Cirrus Logic shows a 52-week-high of $103.25 and a 52-week-low of $55.84. Moreover, at the end of the last trading period, the closing price was at $83.62.</li>
	<li>Needham upgraded the previous rating for Five9 Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) from Hold to Buy. For the second quarter, Five9 had an EPS of $0.23, compared to year-ago quarter EPS of $0.21. The stock has a 52-week-high of $211.68 and a 52-week-low of $107.98. At the end of the last trading period, Five9 closed at $170.19.</li>
	<li>Deutsche Bank upgraded the previous rating for Ventas Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) from Hold to Buy. In the second quarter, Ventas showed an EPS of $0.73, compared to $0.77 from the year-ago quarter. The current stock performance of Ventas shows a 52-week-high of $61.09 and a 52-week-low of $37.83. Moreover, at the end of the last trading period, the closing price was at $56.31.</li>
	<li>For Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), Keybanc upgraded the previous rating of Sector Weight to Overweight. In the second quarter, Spotify Technology showed an EPS of $0.23, compared to $2.10 from the year-ago quarter. The current stock performance of Spotify Technology shows a 52-week-high of $387.44 and a 52-week-low of $201.68. Moreover, at the end of the last trading period, the closing price was at $249.04.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>

&nbsp;

<h2>Downgrades</h2>

<ul>
	<li>Wedbush downgraded the previous rating for XOMA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) from Outperform to Neutral. In the second quarter, XOMA showed an EPS of $0.29, compared to $0.33 from the year-ago quarter. The current stock performance of XOMA shows a 52-week-high of $46.32 and a 52-week-low of $17.66. Moreover, at the end of the last trading period, the closing price was at $28.88.</li>
	<li>For Alliant Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>), Guggenheim downgraded the previous rating of Buy to Neutral. For the second quarter, Alliant Energy had an EPS of $0.57, compared to year-ago quarter EPS of $0.54. The stock has a 52-week-high of $62.35 and a 52-week-low of $45.99. At the end of the last trading period, Alliant Energy closed at $61.47.</li>
	<li>For Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Exane BNP Paribas downgraded the previous rating of Outperform to Neutral. In the fourth quarter, Lam Research showed an EPS of $8.09, compared to $4.78 from the year-ago quarter. The stock has a 52-week-high of $673.80 and a 52-week-low of $292.28. At the end of the last trading period, Lam Research closed at $610.71.</li>
	<li>For Banner Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>), DA Davidson downgraded the previous rating of Buy to Neutral. For the second quarter, Banner had an EPS of $1.56, compared to year-ago quarter EPS of $0.67. The stock has a 52-week-high of $60.42 and a 52-week-low of $30.05. At the end of the last trading period, Banner closed at $56.52.</li>
	<li>According to Morgan Stanley, the prior rating for Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) was changed from Equal-Weight to Underweight. For the second quarter, Vertex Pharmaceuticals had an EPS of $3.11, compared to year-ago quarter EPS of $2.61. The stock has a 52-week-high of $281.86 and a 52-week-low of $185.32. At the end of the last trading period, Vertex Pharmaceuticals closed at $198.05.</li>
	<li>Morgan Stanley downgraded the previous rating for argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) from Overweight to Equal-Weight. In the second quarter, argenx showed an EPS of $1.98, compared to $3.15 from the year-ago quarter. The current stock performance of argenx shows a 52-week-high of $382.15 and a 52-week-low of $212.66. Moreover, at the end of the last trading period, the closing price was at $350.58.</li>
	<li>For Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Morgan Stanley downgraded the previous rating of Overweight to Equal-Weight. Johnson &amp; Johnson earned $2.48 in the second quarter, compared to $1.67 in the year-ago quarter. The current stock performance of Johnson &amp; Johnson shows a 52-week-high of $179.92 and a 52-week-low of $133.65. Moreover, at the end of the last trading period, the closing price was at $175.04.</li>
	<li>Morgan Stanley downgraded the previous rating for Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Overweight to Equal-Weight. In the second quarter, Merck &amp; Co showed an EPS of $1.31, compared to $1.37 from the year-ago quarter. The current stock performance of Merck &amp; Co shows a 52-week-high of $87.80 and a 52-week-low of $15.32. Moreover, at the end of the last trading period, the closing price was at $77.26.</li>
	<li>Wolfe Research downgraded the previous rating for Carrier Global Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) from Outperform to Peer Perform. Carrier Global earned $0.64 in the second quarter, compared to $0.33 in the year-ago quarter. The current stock performance of Carrier Global shows a 52-week-high of $58.89 and a 52-week-low of $28.58. Moreover, at the end of the last trading period, the closing price was at $57.41.</li>
	<li>Morgan Stanley downgraded the previous rating for Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) from Overweight to Equal-Weight. In the second quarter, Amgen showed an EPS of $4.38, compared to $4.25 from the year-ago quarter. At the moment, the stock has a 52-week-high of $276.69 and a 52-week-low of $210.28. Amgen closed at $226.37 at the end of the last trading period.</li>
	<li>For JOANN Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOAN#NASDAQ">JOAN</a>), Barclays downgraded the previous rating of Overweight to Equal-Weight. Interestingly, in the second quarter, JOANN&#39;s EPS was $0.20. The stock has a 52-week-high of $17.50 and a 52-week-low of $9.75. At the end of the last trading period, JOANN closed at $10.28.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>

&nbsp;

<h2>Initiations</h2>

<ul>
	<li>Zelman initiated coverage on Opendoor Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) with a Buy rating. In the second quarter, Opendoor Technologies showed an EPS of $0.24, compared to $0.66 from the year-ago quarter. At the moment, the stock has a 52-week-high of $39.24 and a 52-week-low of $13.44. Opendoor Technologies closed at $19.18 at the end of the last trading period.</li>
	<li>With a Buy rating, Alliance Global Partners initiated coverage on Greenlane Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>). The price target seems to have been set at $6.00 for Greenlane Hldgs. In the second quarter, Greenlane Hldgs showed an EPS of $0.22, compared to $0.46 from the year-ago quarter. The stock has a 52-week-high of $8.73 and a 52-week-low of $1.83. At the end of the last trading period, Greenlane Hldgs closed at $2.73.</li>
	<li>With an Outperform rating, Wedbush initiated coverage on Tango Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>). The price target seems to have been set at $20.00 for Tango Therapeutics. Tango Therapeutics closed at $12.93 at the end of the last trading period.</li>
	<li>With an Overweight rating, Morgan Stanley initiated coverage on Valero Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>). The price target seems to have been set at $80.00 for Valero Energy. In the second quarter, Valero Energy showed an EPS of $0.48, compared to $1.25 from the year-ago quarter. At the moment, the stock has a 52-week-high of $84.95 and a 52-week-low of $35.44. Valero Energy closed at $64.70 at the end of the last trading period.</li>
	<li>Morgan Stanley initiated coverage on Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Equal-Weight rating. The price target for Phillips 66 is set to $80.00. In the second quarter, Phillips 66 showed an EPS of $0.74, compared to $0.74 from the year-ago quarter. At the moment, the stock has a 52-week-high of $94.34 and a 52-week-low of $43.27. Phillips 66 closed at $69.62 at the end of the last trading period.</li>
	<li>With a Equal-Weight rating, Morgan Stanley initiated coverage on PBF Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>). The price target seems to have been set at $12.00 for PBF Energy. For the second quarter, PBF Energy had an EPS of $1.26, compared to year-ago quarter EPS of $3.19. The stock has a 52-week-high of $18.78 and a 52-week-low of $4.06. At the end of the last trading period, PBF Energy closed at $9.63.</li>
	<li>With a Buy rating, Jefferies initiated coverage on Celcuity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>). The price target seems to have been set at $48.00 for Celcuity. In the second quarter, Celcuity showed an EPS of $0.66, compared to $0.17 from the year-ago quarter. At the moment, the stock has a 52-week-high of $33.01 and a 52-week-low of $5.00. Celcuity closed at $21.50 at the end of the last trading period.</li>
	<li>Evercore ISI Group initiated coverage on Avidity Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with an Outperform rating. The price target for Avidity Biosciences is set to $50.00. For the second quarter, Avidity Biosciences had an EPS of $0.70, compared to year-ago quarter EPS of $1.23. The current stock performance of Avidity Biosciences shows a 52-week-high of $37.46 and a 52-week-low of $17.58. Moreover, at the end of the last trading period, the closing price was at $19.24.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Intraday Update

Analyst Ratings

AMGN

ARGX

BANR

CARR

CELC

CRUS

DOMA

DOOO

ELYM

FIVN

GMAB

GNLN

GOEV

JOAN

LRCX

MEOH

NABL

NLCP

OPEN

RKLY

SEYMF

SPOT

SRZN

SSBK

TCBK

TNGX

VRTX

XOMA

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021

Jefferies downgrades Solaria Energia y Medio (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SEYMF#OTC">SEYMF</a>) from Buy to Neutral.

News

Jefferies Downgrades Solaria Energia y Medio to Neutral

Comments

Solaria Energia y Medio

News

Latest news for Solaria Energia y Medio (OTC:SEYMF) Stock

Tuesday, September 07, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga